Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

- Ranexa Revenue Grows 15 Percent Quarter-over-Quarter -

PALO ALTO, Calif., July 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today reported financial results for the second quarter ended June 30, 2008.

For the quarter ended June 30, 2008, the Company reported a net loss of $4.3 million, or $0.07 per share. This compares to a net loss of $31.9 million, or $0.53 per share, for the prior quarter ended March 31, 2008 and $57.6 million, or $0.97 per share, for the same quarter in 2007.

For the quarter ended June 30, 2008, the Company recorded total revenues of $51.6 million which consisted of $25.4 million of net product sales of Ranexa(R) (ranolazine extended-release tablets), $4.0 million of royalty revenue and $22.2 million of license, collaboration and other revenue. The $25.4 million of net product sales for sales of Ranexa represents an increase of 15 percent compared to the $22.0 million of net product sales recorded in the prior quarter ended March 31, 2008. The $4.0 million of royalty revenue includes $2.6 million of amortization of our $175.0 million upfront payment earned from an investment trust related to TPG-Axon Capital in exchange for rights to 50 percent of our royalty on North American sales of Lexiscan(TM) (regadenoson) injection and $1.3 million of Lexiscan(TM) royalty revenue. The $22.2 million of license, collaboration and other revenue includes $12.0 million relating to a milestone payment from Astellas Pharma US. Inc. (Astellas) associated with the U.S. Food and Drug Administration (FDA) approval for Lexiscan(TM) and $10.0 million relating to a milestone payment from TPG-Axon Capital associated with the commercial launch of Lexiscan(TM).

Costs and expenses were $56
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 2015 Glemser Technologies ... EMC® Enterprise Content Division (ECD) Certified Solution Partner ... Documentum® for Life Sciences Solution Suite . The ... capabilities to provide life sciences companies of all ... The EMC Documentum Solution Suite offers four modules: ...
(Date:4/23/2015)... , April 23, 2015 /PRNewswire/ - Crystal Research Associates, ... Informational Overview ® (EIO) on Aeterna Zentaris Inc. ... is available on Crystal Research Associates, website at ... Zentaris, website at www.aezsinc.com . Aeterna ... specialty biopharmaceutical company in oncology, endocrinology, and women,s health. ...
(Date:4/22/2015)... , April 22, 2015  Sangamo BioSciences, Inc. ... 2015 financial results and accomplishments. For the ... consolidated net loss of $5.3 million, or $0.08 per ... or $0.12 per share, for the same period in ... cash, cash equivalents, marketable securities and interest receivable of ...
(Date:4/22/2015)... April 22, 2015 Steep Hill, the ... today that it has opened an investment round ... and expansion.  The common stock investment round will ... a law intended to encourage funding of small ... 506(c), small businesses largely relied on friends and ...
Breaking Biology Technology:Glemser Earns Accreditation for Life Sciences Solution Suite 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... Agreement Enables Spherix to Pursue All Pharmaceutical and Health-Oriented ... June 23 Spherix Incorporated (Nasdaq: SPEX ... a provider of technical and regulatory consulting services to ... it has terminated the 1996 license agreement pursuant to ...
... SAO PAULO, June 23 What does sugarcane have ... successful,30-year experience with sugarcane as a feedstock for ethanol. In ... replace a fossil fuel with,renewable energy has saved some 600 ... years for six billion trees to achieve the same,results. , ...
... , Continuing Supplies Will Be Used For NDA and ... Type 2 Diabetes , , BETHESDA, Md., June ... an innovator in biotechnology for diabetes therapy, and a ... supplement, biotechnology and pharmaceutical companies, today announced that it ...
Cached Biology Technology:Spherix Announces Termination of Arla License Agreement 2Spherix Announces Termination of Arla License Agreement 3Spherix Announces Termination of Arla License Agreement 4Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 2Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 3Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 4Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report ... markets for Hand Geometry in US$ Thousands. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... NT APRIL 2010 High in the Mackenzie Mountains, ... being revealed as warming temperatures melt patches of ice that ... Tom Andrews, an archaeologist with the Prince of Wales Northern ... Polar Year Ice Patch Study, is amazed at the implements ...
... April 26, 2010 Energy in, energy out, it,s the ... more than two thirds of Americans classified as overweight or ... Journal of Nutrition Education and Behavior examines how ... loss programs. Researchers at the University of Kentucky and ...
... 26 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader ... (OK) Sheriff,s Office successful deployment of an FBI-compliant advanced authentication solution for ... authentication. , , , ... http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , , , ...
Cached Biology News:Ancient artifacts reveals as northern ice patches melt 2What's motivation got to do with weight loss? 2BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 2BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 3BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 4
ID clarifier: With ethidium bromide (50 μg/ml)...
... Propidium Iodide (PI) is a fluorescent ... double-stranded nucleic acids. As a nuclear ... to dark red in color. The ... green or blue fluorochromes such as FITC, ...
... were cultured in DMEM and harvested at the ... keep the antigens in their native forms, cells ... arrayed on a 12-well (5 mm) adhesive coated ... enhance cellular attachment and to minimize background staining. ...
...
Biology Products: